150 related articles for article (PubMed ID: 32170181)
1. Validation of CTS5 model in large-scale breast cancer population and the impact of menopausal and HER2 status on its prognostic value.
Wang C; Chen C; Lin Y; Zhou Y; Mao F; Zhu H; Zhang X; Shen S; Huang X; Wang X; Zhao B; Yang J; Sun Q
Sci Rep; 2020 Mar; 10(1):4660. PubMed ID: 32170181
[TBL] [Abstract][Full Text] [Related]
2. Validation of CTS5 Model in Large-scale Breast Cancer Population and Combination of CTS5 and Ki-67 Status to Develop a Novel Nomogram for Prognosis Prediction.
Ning L; Liu Y; He X; Han R; Xin Y; Zhao J; Liu X
Am J Clin Oncol; 2024 May; 47(5):228-238. PubMed ID: 38131531
[TBL] [Abstract][Full Text] [Related]
3. Comparison of CTS5 risk model and 21-gene recurrence score assay in large-scale breast cancer population and combination of CTS5 and recurrence score to develop a novel nomogram for prognosis prediction.
Wang C; Xu Y; Lin Y; Zhou Y; Mao F; Zhang X; Shen S; Zhang Y; Sun Q
Breast; 2022 Jun; 63():61-70. PubMed ID: 35334240
[TBL] [Abstract][Full Text] [Related]
4. The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
Tajiri W; Ijichi H; Takizawa K; Koi Y; Masuda T; Ueo H; Koga C; Nakamura Y; Taguchi K; Okamoto M; Tokunaga E
Breast Cancer; 2021 Jan; 28(1):67-74. PubMed ID: 32601800
[TBL] [Abstract][Full Text] [Related]
5. Validation of CTS5 on a Retrospective Cohort of Real-Life Pre- and Postmenopausal Patients Diagnosed With Estrogen Receptor-Positive Breast Cancers: Is It Prognostic?
Villasco A; Agnelli F; D'Alonzo M; Accomasso F; Sismondi P; Biglia N
Clin Breast Cancer; 2021 Feb; 21(1):e53-e62. PubMed ID: 32703705
[TBL] [Abstract][Full Text] [Related]
6. Validation of the Clinical Treatment Score Post-Five Years in Breast Cancer Patients for Predicting Late Distant Recurrence: A Single-Center Investigation in Korea.
Lee JH; Lee SK; Chae BJ; Yu J; Lee JE; Kim SW; Nam SJ; Ryu JM
Front Oncol; 2021; 11():691277. PubMed ID: 34239805
[TBL] [Abstract][Full Text] [Related]
7. Would 1.0 cm be a more suitable cutoff to subdivide pT1 tumors in hormone receptor-negative and HER2-positive breast cancer?
Wang C; Zhou Y; Zhu H; Huang W; Chen Z; Mao F; Lin Y; Zhang X; Shen S; Zhong Y; Li Y; Sun Q
Cancer Med; 2018 Nov; 7(11):5420-5430. PubMed ID: 30277006
[TBL] [Abstract][Full Text] [Related]
8. Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer.
Richman J; Ring A; Dowsett M; Sestak I
Breast Cancer Res Treat; 2021 Feb; 186(1):115-123. PubMed ID: 33222093
[TBL] [Abstract][Full Text] [Related]
9. Impact of Breast Cancer Subtypes on Prognosis of Women with Operable Invasive Breast Cancer: A Population-based Study Using SEER Database.
Hwang KT; Kim J; Jung J; Chang JH; Chai YJ; Oh SW; Oh S; Kim YA; Park SB; Hwang KR
Clin Cancer Res; 2019 Mar; 25(6):1970-1979. PubMed ID: 30559169
[TBL] [Abstract][Full Text] [Related]
10. Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index.
Lee J; Cha C; Ahn SG; Kim D; Park S; Bae SJ; Kim J; Park HS; Park S; Kim SI; Park BW; Jeong J
Sci Rep; 2020 Oct; 10(1):16850. PubMed ID: 33033359
[TBL] [Abstract][Full Text] [Related]
11. Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
Dowsett M; Sestak I; Regan MM; Dodson A; Viale G; Thürlimann B; Colleoni M; Cuzick J
J Clin Oncol; 2018 Jul; 36(19):1941-1948. PubMed ID: 29676944
[TBL] [Abstract][Full Text] [Related]
12. Clinical Treatment Score post-5 years as a predictor of late distant recurrence in hormone receptor-positive breast cancer: systematic review and meta-analysis.
Shrestha A; Cullinane C; Evoy D; Geraghty J; Rothwell J; Walshe J; McCartan D; McDermott E; Prichard R
Br J Surg; 2022 Apr; 109(5):411-417. PubMed ID: 35194632
[TBL] [Abstract][Full Text] [Related]
13. Establishing a predicted model to evaluate prognosis for initially diagnosed metastatic Her2-positive breast cancer patients and exploring the benefit from local surgery.
Lin H; Wu Y; Liang G; Chen L
PLoS One; 2020; 15(11):e0242155. PubMed ID: 33170907
[TBL] [Abstract][Full Text] [Related]
14. Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials.
Noordhoek I; Blok EJ; Meershoek-Klein Kranenbarg E; Putter H; Duijm-de Carpentier M; Rutgers EJT; Seynaeve C; Bartlett JMS; Vannetzel JM; Rea DW; Hasenburg A; Paridaens R; Markopoulos CJ; Hozumi Y; Portielje JEA; Kroep JR; van de Velde CJH; Liefers GJ
J Clin Oncol; 2020 Oct; 38(28):3273-3281. PubMed ID: 32706636
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
Li X; Zhang X; Liu J; Shen Y
BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
[TBL] [Abstract][Full Text] [Related]
16. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
17. Molecular Subtypes and Prognostic Factors among Premenopausal and Postmenopausal Thai Women with Invasive Breast Cancer: 15 Years Follow-up Data.
Tubtimhin S; Promthet S; Suwanrungruang K; Supaattagorn P
Asian Pac J Cancer Prev; 2018 Nov; 19(11):3167-3174. PubMed ID: 30486605
[TBL] [Abstract][Full Text] [Related]
18. Clinical Treatment Score Post-5 Years as a Tool for Risk Estimation of Late Recurrence in Thai Patients With Estrogen-Receptor-Positive, Early Breast Cancer: A Validation Study.
Dejthevaporn T; Patanayindee P
Breast Cancer (Auckl); 2023; 17():11782234231186869. PubMed ID: 37533837
[TBL] [Abstract][Full Text] [Related]
19. Different patterns in the prognostic value of age for breast cancer-specific mortality depending on hormone receptor status: a SEER population-based analysis.
Liu YR; Jiang YZ; Yu KD; Shao ZM
Ann Surg Oncol; 2015 Apr; 22(4):1102-10. PubMed ID: 25249260
[TBL] [Abstract][Full Text] [Related]
20. The Prognostic Significance of the Oncotype DX Recurrence Score in T
Wang M; Wu K; Zhang P; Zhang M; Ding A; Chen H
Ann Surg Oncol; 2019 May; 26(5):1227-1235. PubMed ID: 30456680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
